“Blessed are the peacemakers,” Trump wrote on social media. Well, they sure are, Mr. President, and now that you have brought ...

Analysts have reacted positively to news that the US Food and Drug Administration (FDA) has lifted the clinical hold on ...

Amyotrophic lateral sclerosis may involve an autoimmune component — a finding that could reshape treatment strategies and ...

Researchers identified immune cells that attacked the neuronal protein C9orf72 in individuals with ALS, spurring new ...

Northwestern University professor Hande Ozdinler is hoping to change how ALS is treated, saying the disease is too complex ...

Researchers identified three subtypes of amyotrophic lateral sclerosis, each with distinct mechanisms that could be future ...

Neurodegenerative diseases are marked by the progressive and irreversible decline of neuron function within specific brain regions, including Alzheimer's, ...

While the overall trial did not meet its primary and secondary endpoints, Neuronata-R ® showed meaningful efficacy in patients with slower disease progression. These findings confirm Neuronata-R ® 's ...

Meaningful improvements confirmed in slow-progressor subgroup; biomarker reductions support precision-medicine approach and potential FDA accelerated pathway These findings confirm Neuronata-R ® 's ...

SEOUL, South Korea, Sept. 17, 2025 /PRNewswire/ -- CorestemChemon Inc. (KOSDAQ: 166480) announced today that it has presented key findings from the Phase 3 ALSummit trial of Neuronata-R® ...